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The relative capacities of muscarinic cholinergic receptor (MR) and bradykinin (BK)-receptor activation to
increase phosphoinositide hydrolysis and to increase cytosolic Ca2" were compared in NG108-15
neuroblastoma x glioma and 1321N1 human astrocytoma cells. In 1321N1 cells, the muscarinic cholinergic
agonist carbachol and BK each stimulated a concentration-dependent accumulation of inositol phosphates
(KO5 1/OtM and 1O nm respectively) and a rapid increase in cytosolic Ca2" as determined by quin2
fluorescence. In NG108-15 cells, BK alone stimulated a pertussis-toxin-insensitive accumulation of inositol
phosphates (Ko5 - 10 nM) under conditions in which pertussis toxin completely inhibited MR-mediated
inhibition of adenylate cyclase. BK also stimulated a rapid increase in cytosolic Ca2" in NG108-15 cells. In
contrast, no MR-mediated increase in phosphoinositide hydrolysis or change in cytosolic Ca2" concentration
was observed in NG108-15 cells. These results support the idea that MR selectively interact with either the
cyclic AMP or the inositol phosphate second-messenger systems.
INTRODUCTION
Stimulation of muscarinic cholinergic receptors (MR)
results in the activation of various transmembrane
signalling systems. These include (1) the direct inhibition
of adenylate cyclase and a decrease in cyclic AMP
(reviewed by Harden et al., 1986), (2) the direct activation
of phospholipase C and an increase in the cellular
inositol phosphate (InsP) and diacylglycerol concentra-
tions (reviewed by Harden et al., 1986), (3) an InsP-
induced increase in cytosolic Ca2", followed in turn by an
increase in the cellular concentrations of arachidonate
(DeGeorge et al., 1987) and cyclic GMP (McKinney &
Richelson, 1984), and (4) the regulation of a variety of
membrane ion conductances (reviewed by North, 1986).
Although the existence of MR subtypes has been
proposed on the basis of pharmacological data (Goyal &
Rattan, 1978; Hammer & Giachetti, 1982), a clear
association of putative receptor subtypes with particular
biochemical responses has not been established.
1321N1 human astrocytoma cells express a pharma-
cologically homogeneous population ofMR that respond
to cholinergic stimuli with an increase in InsP formation
and mobilization of intracellular Ca2" (Masters et al.,
1984). MR-mediated inhibition of adenylate cyclase does
not occur in these cells (Meeker & Harden, 1982), and,
although fully functional Gi is present, inactivation of
this protein by pertussis toxin has no effect either on
MR-mediated responses of intact 132INI cells (Hughes
et al., 1984; Masters et al., 1985) or on GTP-sensitive
high-affinity binding of cholinergic agonists to washed
1321NI-cell membranes (Evans et al., 1985). Thus MR
on these cells apparently do not interact with Gi, the
protein that couples inhibitory receptors to adenylate
cyclase.
The data for 132INI cells initially were surprising in
that regulation ofadenylate cyclase is a well-characterized
property of MR in other tissues. One potential explan-
ation for these results is that a MR subtype exists on
1321NI cells that selectively interacts with the putative
G-protein that regulates phospholipase C activity (Taylor
& Merritt, 1986), but that does not interact with G., the
G-protein that regulates adenylate cyclase. If this is true,
then an analogous but opposite selectivity might be
expected for the MR subtype that regulates adenylate
cyclase. That is, this receptor would couple to Gi and
adenylate cyclase, but not to the membrane machinery
responsible for hormonal regulation of phosphoinositide
mnetabolism. Consistent with this proposal, NG 108-15
neuroblastoma x glioma cells express a pharmacologic-
ally homogeneous population of MR that interact with
Gi to inhibit adenylate cyclase activity (Sabol &
Nirenberg, 1979; Lichtshtein et al., 1979; Kurose et al.,
1983; Smith & Harden, 1984). Although stimulation of
bradykinin (BK) receptors on NG108-15 cells results in
the activation of phospholipase C and formation of
inositol phosphates (Yano et al., 1985), it has not been
shown whether activation of MR on these cells also
results in the hydrolysis of phosphoinositides. We report
that no MR-mediated regulation of InsP formation or
Ca2" mobilization occurs in NG108-15 cells under
conditions where a fully functional, pertussis-toxin-
insensitive and BK-receptor-mediated phosphoinositide/
Ca2" response system is operative. Conversely, stimu-
lation of both MR and BK receptors on 1321N1 cells
results in the formation of InsP and a mobilization of
Ca2". These data are consistent with the idea that
1321N1 and NG108-15 cells each express a homogeneous
population ofMR that are functionally distinct, and that
MR subtypes can be distinguished on the basis of their
Abbreviations used: MR, muscarinic cholinergic receptors; InsP, total inositol phosphates, including inositol monophosphate, inositol
bisphosphate, inositol trisphosphate and inositol tetrakisphosphate; BK, bradykinin; Gp, the guanine nucleotide binding protein that couples
inhibitory receptors to adenylate cyclase; G-protein, any member of a related family of guanine nucleotide binding regulatory proteins.
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Fig. 1. Effects of carbachol or BK on InsP and cytosolic Ca2l concentrations in 1321N1 and NG108-15 cells
1321N1 and NG108-15 cells were labelled overnight with myo-[3H]inositol (a and c), or loaded with the fluorescent Ca2l
indicator quin2 (b and d) as described in the Methods section. (a) myo-[3H]inositol-labelled 1321N1 or (c) NG108-15 cells were
exposed to vehicle, the indicated concentrations of carbachol (CARB; *), or the indicated concentrations of BK (0) for
10 min in the presence of 10 mM-LiCl. Data are presented as the percentage of the maximal increase in [3H]InsP-associated
radioactivity stimulated by carbachol in 1321N1 cells (1506+ 176 c.p.m.; mean+S.E.M.) or BK in NG108-15 cells (1762+85).
Basal radioactivity (207+9 and 271 + 11 c.p.m. for 1321N1 and NG108-15 cells respectively) was subtracted from the data
presented. Data are means of triplicate determinations and are representative of three experiments. (b) Quin2-loaded 1321N1
cells were exposed to vehicle, 500 /M-carbachol, carbachol followed by 10 M-atropine (ATRO), or 1O#M-BK. Resting free
Ca2+ concentration (mean+S.E.M.) was 111+ 16 nM (n = 8), and carbachol and BK stimulated a 3.2- and a 2.8-fold rise in
cytosolic free Ca2+ concentration respectively. (d) Quin2-loaded NG108-15 cells were exposed to vehicle, 1 mM-carbachol or
1 uM-BK. Resting free Ca2' concentration was 123 + 24 nM (n = 7), and BK stimulated a 2-fold rise in cytosolic free Ca2+
concentration.




132INI human astrocytoma and NG108-15 neuro-
blastoma x glioma cells were grown as previously de-
scribed (Hughes et al., 1984).
Measurement of inositol pbosphate accumulation
Labelling of the cells with myo-[3H]inositol and
measurement of InsP by anion-exchange chromato-
graphy were as previously described (Nakahata et al.,
1986). Briefly, 132INI and NG108-15 cells were labelled
overnight with 1 /XCi of myo-[3H]inositol/ml and exposed
to carbachol, BK or vehicle for 10 min in the presence of
10 mM-LiCl. The reaction was stopped by the addition of
methanol, inositol phosphates were extracted by the
addition of chloroform and water, and water-soluble
[3H]inositol phosphates were collected by anion-
exchange chromatography.
Measurement of intracellular Ca2"
Cells were suspended in Hepes-buffered Eagle's mini-
mal essential medium and then loaded with the fluor-
escent Ca2" indicator quin2 by incubation with 50/tM-
quin2/AM for 30 min at 37 °C in the dark as previously
described (Tsien et al., 1982). Cells were washed free of
extracellular quin2/AM by centrifugation (twice for
5 min at 100 g), resuspended in Hepes-buffered saline
(pH 7.5), and maintained at room temperature. Cells
(2 x 106-3 x 106 cells/ml) were monitored for changes
in quin2 fluorescence with a Perkin-Elmer Hitachi
MPF-2.A fluorescence spectrophotometer. Under these
conditions, over 85% of the cells remained viable, as
determined by Trypan Blue exclusion under microscopic
examination. Determination of intracellular free Ca2"
concentration on the basis of quin2 fluorescence was
as previously described (Tsien et al., 1982).
Pertussis-toxin treatment of cells
Cells were treated overnight with various concentra-
tions of pertussis toxin as described previously (Hughes
et al., 1984).
Materials
Carbachol and atropine were obtained from Sigma
Chemical Co. (St. Louis, MO, U.S.A.), BK and quin2/
AM from Calbiochem (San Diego, CA, U.S.A.),
{3H]adenine (40 Ci/mmol) was from ICN (Irvine, CA,
U.S.A.), and myo-[3H]inositol (15 Ci/mmol) from ARC
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Fig. 2. Differential effects of pertussis toxin on BK-stimulated
InsP accumulation and MR-mediated inhibition of cyclic
AMP accumulation in NG108-15 cells
NG108-15 cells were labelled overnight with myo-
[3H]inositol in the presence (+PT) or absence (-PT) of
300 ng of pertussis toxin/ml. Cells were challenged with
vehicle (-) or 1 #aM-bradykinin (BK) for Omin in the
presence of 10 mM-LiCl. Companion NG108-15 cells were
incubated overnight with vehicle or the indicated concen-
trations of pertussis toxin as described by Hughes et al.
(1984). The cells were incubated for 60 min with 1 ,uCi of
[3H]adenine/ml, and challenged with 1 /SM-prostaglandin
E1 alone or in the presence of 100 #sM-carbachol for
10 min. The results are plotted as the percentage inhibition
of cyclic AMP accumulation observed in the presence of
carbachol (@). The data are from quadruplicate determin-
ations and are representative of three experiments.
(St. Louis, MO, U.S.A.). Pertussis toxin was prepared as
previously described (Hughes et al., 1984).
RESULTS
Carbachol is an efficacious stimulator of InsP forma-
tion in 1321N1 human astrocytoma cells (Masters et al.,
1984; Fig. la). In addition, BK markedly stimulated
InsP formation in these cells (Fig. la). In confirmation of
the data of Yano et al. (1985), BK also markedly
stimulated InsP formation in NG108-15 cells (Fig. 1c).
The KI(. values for BK were approximately the same
(- 3-10 nM) for NG108-15 and 1321N1 cells. In contrast
with the results obtained in 132INI cells, carbachol at
concentrations up to 10 mm had no effect on InsP
formation in NG108-15 cells (Fig. lc).
Since it has been demonstrated that InsP formation is
linked to the mobilization of Ca2" in a wide variety of
tissues (Berridge, 1987), it was also important to
determine if stimulation of MR produced an increase in
cytosolic Ca2" in NG108-15 cells. Therefore Ca2"
concentrations measured with the fluorescent Ca2"
indicator quin2 were compared in hormone-stimulated
1321N1 and NG108-15 cells. Activation of MR on
1321N1 cells increased intracellular Ca2" (Fig. lb). This
effect was maintained for at least 5 min in the presence of
agonist and was reversed by addition of atropine.
Consistent with its observed effects on InsP formation,
BK also increased intracellular Ca2" in 1321N1 cells (Fig.
lb). Although BK also increased intracellular Ca2" in
NG108-15 cells, carbachol was without effect (Fig. lb).
NG 108-15 cells express a relatively high density ofMR
that markedly inhibit adenylate cyclase activity on
activation (Sabol & Nirenberg, 1979; Lichtshtein et al.,
1979; Smith & Harden, 1984). As previously demon-
strated in these cells (Kurose et al., 1983), carbachol
caused a 70 % inhibition of cyclic AMP accumulation in
NG108- 15 cells that was completely reversed by pertussis
toxin at concentrations as low as 3 ng/ml (Fig. 2). In
contrast, preincubation ofNG108-15 cells with 300 ng of
pertussis toxin/ml had no effect on BK-stimulated InsP
formation (Fig. 2).
DISCUSSION
The presence of G, or a 'Gi-like' protein in NG 108-15
neuroblastoma x glioma cells apparently fully accounts
for MR-G-protein coupling in these cells, in that
pertussis toxin or low concentrations of N-ethylmale-
imide, which both have been shown to inactivate Gi,
abolish GTP-sensitive high-affinity binding of agonists
to MR (Kurose et al., 1983; Smith & Harden, 1984;
Evans et al., 1985) and MR-mediated inhibition of
adenylate cyclase activity (Kurose et al., 1983; and Fig.
2). The current study confirms the report by Yano et al.
(1985), which demonstrated that BK markedly stimulates
phospholipase C activity in NG108-15 cells. Moreover,
as illustrated above, inactivation of Gi with pertussis
toxin had no effect on BK-stimulated InsP formation.
Thus, as with the phosphoinositide response to mus-
carinic agonists (Hepler & Harden, 1986) and BK (J. R.
Hepler, unpublished work) observed in 1321Nl cells,
BK-receptor-mediated activation of phospholipase C in
NG108-15 cells apparently does not involve G. or a
similar pertussis-toxin substrate.
Although Siman & Klein (1981) have reported that
carbachol stimulates a small increase in 32P labelling of
phosphatidylinositol in a clone of NG108-15 cells, the
present paper demonstrates that activation of MR on
these cells does not result in phosphoinositide hydrolysis
and InsP formation. This lack of response to carbachol
was further supported by the fact that Ca2+ concentra-
tions, measured with quin2, did not change in response
to MR agonists. Thus, although a functional population
of MR and a fully functional BK-receptor-responsive
phospholipase C are both present in NG108-15 cells,
stimulation of MR does not activate phospholipase C
and phosphoinositide hydrolysis. These results are the
opposite of those observed in 1321N1 cells, in which MR
interact with components of the phosphoinositide re-
sponse cascade but do not interact with the adenylate
cyclase system. Thus, at least in data obtained with two
cloned cell lines, MR couple to either the InsP or the
cyclic AMP response system, but not to both. Owing to
problems of cellular heterogeneity and lack of availability
ofMR antagonists that selectively block one or the other
of the second-messenger responses, it has not been
possible to make similar conclusions from studies with
mammalian tissues. The rigid signalling specificity ex-
pressed by the two cell lines potentially could be explained
by some vagary of cultured cell lines. However, the
phosphoinositide and cyclic AMP response systems of
both cell lines are, in all ways tested to date, fully
functional and receptor-operated. Thus it seems appro-
priate to generalize from the data presented here and to
Vol. 247
795
796 J. R. Hepler, A. R. Hughes and T. K. Harden
suggest that it is indicative of the existence of two forms
of MR. One type of receptor protein possesses a
polypeptide sequence that readily interacts with Gi, and
thus inhibits adenylate cyclase. The other proposed
receptor type expresses a polypeptide sequence that
selectively interacts with the pertussis-toxin-insensitive
G-protein involved in the activation of phospholipase C.
Whether this selectivity ofMR interaction with different
G-proteins is absolute under all conditions and in all
tissues cannot be concluded from the results reported
here. There is evidence that the receptor proteins of NG-
108-15 and 1321N1 cells are structurally distinct. That is
the MR of the two cell lines have been labelled covalently
with [3H]propylbenzylcholine mustard (Liang et al.,
1987), and the apparent size of the specifically labelled
receptors differed by approx. 20000 Da after SDS/
polyacrylamide-gel electrophoresis under a variety of
conditions.
Putative M1- and M2-muscarinic receptor subtypes
have been proposed on the basis of pharmacological and
radioligand-binding data obtained with the antagonist
pirenzepine (Goyal & Rattan, 1978; Hammer & Gia-
chetti, 1982). Although Gil & Wolfe (1985) have
presented data with rat brain indicating that pirenzepine
blocks the InsP response to MR agonists at lower
concentrations than those necessary to block the cyclic
AMP response, several studies using other tissues have
failed to confirm a selectivity of pirenzepine for blockade
of these responses (Lazareno et al., 1985; Brown et al.,
1985; Fisher, 1986). Thus it is yet to be established
whether the MR subtypes proposed on the basis of
selectivity of interaction with second-messenger systems
can be segregated according to the previously proposed
M1-M2MR subtypes. The observations (Logothetis et
at., 1987; Yatani et al., 1987) that MR activate K+
channels directly in some tissues, apparently by inter-
acting with a G-protein, underscores further the diffi-
culties of characterizing MR subtypes.
It is clear that more selective ligands are needed to
establish unequivocally the existence of pharmaco-
logically distinct MR subtypes. However, our data with
cultured NG108-15 and 1321N1 cells suggest that two
MR can be delineated at the level of interaction with
second-messenger systems. As such, these two cell lines
should prove useful in further development of under-
standing of the pharmacological and biochemical proper-
ties of MR.
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